Precancerous lesions of the stomach, gastric cancer and hereditary gastric cancer syndromes
Gastric cancer accounts for about 6% of cancers worldwide, being the fifth most frequently diagnosed malignancy and the third leading cause of cancer related death. Gastric carcinogenesis is a multistep and multifactorial process and is the result of the complex interplay between genetic susceptibility and environmental factors. The identification of predisposing conditions and of precancerous lesions is the basis for screening programs and early stage treatment. Furthermore, although most gastric cancers are sporadic, familial clustering is observed in up to 10% of patients. Among them, hereditary cases, related to known cancer susceptibility syndromes and/or genetic causes are thought to account for 1-3% of all gastric cancers. The pathology report of gastric resections specimens therefore requires a standardized approach as well as in depth knowledge of prognostic and treatment associated factors.
Gastric cancer accounts for about 6% of cancers worldwide, being the fifth most frequently diagnosed malignancy and the third leading cause of cancer related death, behind lung and colorectal cancer. According to the most recent GLOBOCAN cancer estimates, gastric cancer was responsible for over 1,000,000 new cancer cases and 783,000 deaths in 2018 1. Although there has been a steady decline in the incidence and mortality of gastric cancer over the last 15 years, as the result of the decrease of Helicobacter pylori prevalence and better dietary habits, the absolute incidence rate continues to rise, due to the advancing age of the world population.
Gastric cancer incidence and mortality vary substantially across countries and within each country. Incidence rates are elevated (up to 32 cases per 100,000) in Eastern and Western Asia. Zones of low incidence (< 7 cases per 100,000) are Northern America, Northern Europe, and most regions of Africa 1. In Italy, gastric cancer ranks eighth among all cancers, with 12,803 new cases and 9,457 deaths in 2018 1. The poor clinical outcome of gastric cancer is mainly due to late diagnosis, poor response to therapeutic regimens and the highly heterogenous nature of the disease 2.
Gastric carcinogenesis is a multistep and multifactorial process and is the result of the complex interplay between genetic susceptibility and environmental factors. Risk factors predisposing to gastric cancer include Helicobacter pylori infection, tobacco smoking, dietary habits 3 (high intake of salt-preserved, smoked foods, red and processed meat, low intake of fresh fruit and vegetables), and Epstein-Barr virus (EBV) infection 4, as well as microbial community modifications by long-term use of proton-pomp inhibitors 5. A number of precancerous conditions have been recognized, such as chronic atrophic gastritis and intestinal metaplasia due to Helicobacter pylori infection or autoimmunity (pernicious anemia), peptic ulcer disease, gastric stump after partial gastrectomy and gastric polyps.
Although most gastric cancers are sporadic, familial clustering is observed in up to 10% of patients. Among them, hereditary cases, related to known cancer susceptibility syndromes and/or genetic causes are thought to account for 1-3% of all gastric cancers 6,7. The three major hereditable syndromes that primarily affect the stomach are hereditary diffuse gastric cancer (HDGC), gastric adenocarcinoma, proximal polyposis of the stomach (GAPPS), and familial intestinal gastric cancer (FIGC).
ATROPHIC GASTRITIS AND INTESTINAL METAPLASIA
Gastric carcinogenesis is a multistep process which involves, in most cases, a progression from normal mucosa through chronic gastritis (chronic inflammation of the gastric mucosa), mucosal atrophy (loss of gastric glands) and intestinal metaplasia (substitution of gastric epithelium by intestinal epithelium) to dysplasia (intraepithelial neoplasia) and carcinoma. This sequence of events may last several years and has been designated as the Correa’s cascade of multistep gastric carcinogenesis 8. According to this model, long standing inflammation is the primary pathogenic factor leading to gastric cancer development.
Among environmental factors leading to inflammation-mediated gastric cancer, Helicobacter pylori infection is associated with almost 90% of new cases of non-cardia gastric cancers 9 and was classified as a type I carcinogen by the WHO in 1994. Approximately half of the world’s population is infected with Helicobacter pylori, however, only a small fraction will end up developing gastric carcinoma, suggesting that additional factors participate in the carcinogenic process, including Helicobacter pylori virulence factors, genetic susceptibility, diet, smoking, and possibly other bacteria species 10. Helicobacter pylori virulence factors that appear to influence the pathogenicity of the bacterium, as well as the risk of gastric cancer development, include CagA (cag pathogenicity island-encoded cytotoxin associated gene A) and VacA (vacuolating cytotoxin A) 11, while polymorphisms of genes involved in initiation and modulation of the inflammatory response, such as genes codifying IL-1β, IL-1 receptor antagonist, IL-10 and TNFα, are host genetic susceptibility factors associated with individual or familial susceptibility to carcinogenesis mediated by Helicobacter pylori infection 12. Although the magnitude of risk is not uniformly defined, atrophic gastritis caused by autoimmunity (pernicious anemia) is associated with an increased risk of dysplasia and adenocarcinoma 13, as well as neuroendocrine neoplasms and gastric epithelial polyps, such as intestinal-type adenomas and pyloric gland adenomas.
Several classification systems for chronic gastritis have been developed, including the Sydney classification system 14, the Gastric Risk Index 15 and the Operative Link on Gastritis Assessment (OLGA) system 16. These staging systems, particularly the five-tiered (0-IV) OLGA system, provide a basis for predicting gastric cancer risk associated with atrophic gastritis and intestinal metaplasia and guide clinical surveillance 17.
Well established evidence links intestinal metaplasia to intestinal-type gastric cancer 18. Complete intestinal metaplasia shows goblet cells, absorptive enterocytes with luminal brush border and intestinal mucin (MUC2) expression. In contrast, incomplete intestinal metaplasia displays globet cells, absorptive cells without brush border and co-expression of intestinal and gastric (MUC5AC, MUC6) mucins 19. Reliable indicators of gastric cancer risk include the topographical extent of intestinal metaplasia and the degree of incomplete-type intestinal metaplasia 20.
Another pattern of metaplasia, which is believed to represent an alternative pathway to gastric neoplasia, is pseudopyloric or spasmolytic polypeptide-expressing metaplasia (SPEM), which expresses trefoil factor family 2 (TFF2) spasmolytic polypeptide and represents the metaplastic replacement of oxyntic glands by mucin secreting antral-like glands. SPEM develops in the gastric body and fundus and has been associated with chronic Helicobacter pylori infection and development of gastric cancer 21.
Gastric dysplasia is defined as unequivocal neoplastic changes in the gastric epithelium, without evidence of lamina propria invasion. The diagnostic criteria are based on the presence of cellular atypia, abnormal differentiation, architectural disorganisation and increased mitotic activity. Endoscopically, gastric dysplasia may present as flat, depressed or polypoid lesions (the latter may be referred to as gastric – intestinal type and foveolar type – adenomas). It may arise de novo or may occur within pre-existing benign sporadic polyps, namely hyperplastic polyps and fundic gland polyps or hamartomatous polyps, such as juvenile polyps and Peutz-Jeghers polyps.
On the basis of the histomorphological profile, gastric dysplasia may be classified as intestinal or foveolar (gastric) type. Intestinal type dysplasia shows features resembling colonic adenomas, with tubular glands lined by columnar cells with overlapping, pseudostratified and penicillate nuclei, which can be hyperchromatic and/or pleomorphic. Differentiation towards goblet cells, absorptive cells and Paneth cells may be observed. Intestinal type dysplasia shows immunoreactivity for MUC2, CD10 and CDX2 22. The foveolar (gastric) phenotype is characterized by cuboidal to low columnar cells resembling gastric foveolar cells, with round to oval nuclei and clear or eosinophilic cytoplasm. Gastric differentiation may be confirmed by MUC5AC and MUC6 expression. Using immunohistochemistry, hybrid or mixed cases may also occur, with both intestinal and gastric marker expression, as well as null cases, negative for the aforementioned markers. Foveolar type dysplasia is more likely to be high-grade and is associated more frequently to gastric adenocarcinoma 22.
Dysplasia is graded as low grade or high grade on the basis of architectural distortion, nuclear and cytoplasmic cell features and mitotic activity. In low grade dysplasia, glandular architecture is relatively preserved, cellular pleomorphism is mild or absent, nuclei maintain basal polarity and mitotic activity is not markedly increased. High grade dysplastic features include complex glandular architecture, marked cytologic atypia with large nuclei and prominent nucleoli, loss of cell polarity and frequent mitotic figures 23. Distinction between high-grade dysplasia and intramucosal intestinal adenocarcinoma may be challenging, especially in small biopsy samples, and there is only limited consensus about diagnostic criteria, especially between Asian and Western pathologists. Helpful features for the diagnosis of intramucosal adenocarcinoma include marked glandular crowding, cribriform and crawling pattern, budding, infiltration of isolated cells and intraglandular necrotic debris (Fig. 1). The presence of desmoplasia is not necessary for the definition of stromal invasion. The distinction between reactive/regenerative changes and true dysplasia may be difficult, especially in small biopsies and specimens with technical artefacts. For these cases, the term “indefinite for dysplasia” may be applied. Gastric dysplasia limited to the pit region, without superficial epithelial involvement, is defined as crypt dysplasia 24.
A recent classification proposed by Hackeng WM et al. 25. distinguishes gastric polyps according to the gastric mucosa compartment from which the gastric polyp arises. Gastric adenomas arising from the foveolar compartment include foveolar type adenomas (arising from foveolar epithelium without intestinal metaplasia) (Fig. 2a) and intestinal type adenomas (arising from foveolar epithelium with intestinal metaplasia) (Fig. 2b). Gastric adenomas arising from the glandular compartment include pyloric gland adenoma (PGA) (Fig. 2c) and oxyntic gland adenoma (OGA). Consistent with their glandular histogenesis, OGAs and PGAs show diffuse immunoreactivity for MUC6.
PGAs consist of closely packed tubules or dilated glands of pyloric type epithelium, lined by cuboidal/low columnar cells with pale, clear or slightly eosinophilic cytoplasm. PGAs may occur in syndromic contexts, namely familial adenomatous polyposis (FAP) and Lynch syndrome 26.
OGAs is composed of dysplastic glands showing variable differentiation to chief and parietal cells. There is a morphological continuum between OGA and gastric adenocarcinoma of fundic gland type. Whether they are distinct lesions, the former representing the precursor lesion of the latter, or represent a morphological spectrum of the same lesion is still debated 27.
BENIGN GASTRIC POLYPS WITH POSSIBLE GASTRIC DYSPLASIA AND GASTRIC CANCER
Hyperplastic polyps (HPs) are benign gastric epithelial lesions consisting of hyperplastic and cystically dilated foveolar epithelium, in a background of prominent inflammatory changes. As HPs represent a hyperproliferative response to tissue injury, most of them arise in a background of longstanding gastric mucosal inflammation and are the prevalent polyp type in countries with a high prevalence of Helicobacter pylori infection. Foveolar or intestinal type dysplasia and adenocarcinoma (intestinal type or diffuse type) may arise in about 2% of larger HPs 28 (Fig. 3). Copy number alterations and TP53 mutations are restricted to the adenocarcinoma component 29.
Fundic gland polyps (FGPs) are benign gastric epithelial lesions composed of disordered, expanded and cystically dilated oxyntic glands lined by parietal and chief cells, as well as mucous neck epithelium. FGPs are the predominant polyp type in Western countries, are associated with the use of proton pomp inhibitors and are inversely related to Helicobacter pylori gastritis 30. FGPs may develop foveolar-type dysplasia, which is usually low-grade (Fig. 4). In sporadic FGPs, dysplasia is rarely observed and the finding of dysplasia should raise suspicion of an inherited syndrome, especially in the case of young patients, multiple FGPs and (in the case of FAP) polyps elsewhere in the gastrointestinal tract. In the syndromic context, dysplasia in FGPs may be observed in gastric adenocarcinoma and proximal polyposis of the stomach (see below) and FAP. The genomic landscape of syndromic and sporadic FGPs is distinctive. FAP-associated FGPs may present second-hit inactivation of the APC gene but no CTNNB1 (beta-catenin) mutations, while sporadic FGPs harbour CTNNB1 mutations and usually lack APC alterations 31.
Gastric adenocarcinoma is a malignant epithelial neoplasm with glandular differentiation arising from the gastric mucosa and represents a biologically heterogeneous group of tumors with respect to etiology, histogenesis, morphology, and molecular features. Overall, gastric adenocarcinoma accounts for 90-95% of gastric malignancies.
According to the depth of invasion in the gastric wall, gastric cancer is classified as early or advanced. Early gastric cancer is defined as a carcinoma limited to the mucosa (pT1a) or the mucosa and submucosa (pT1b), regardless of tumor size or the presence of lymph-node metastases. Gastric adenocarcinomas invading the muscularis propria and beyond (> pT2) are defined as advanced.
The clinical presentation of gastric cancer is mainly related to topography and stage of the disease. The majority of early gastric cancers are asymptomatic at diagnosis. Screening programs in high-risk populations (Japan, Korea) have resulted in early diagnosis in asymptomatic patients and better overall survival 32. At advanced disease stage, common signs and symptoms include dyspepsia, epigastric pain, abdominal mass and alarm symptoms (“red flags”), such as dysphagia, significant weight loss, signs and symptoms of gastrointestinal hemorrhage and vomiting.
Endoscopic examination with biopsies is the gold standard method for gastric cancer diagnosis. Image enhanced endoscopy and magnifying endoscopy may improve the detection rate of early gastric lesions 33.
Accurate (TNM) staging is the cornerstone for accurately defining gastric cancer prognosis and therapeutic approaches. Compared to advanced gastric cancers, early gastric cancers have a much better prognosis, with a 5-year survival rate of > 90% after surgical resection. If untreated, 63% of early gastric carcinomas progress to advanced tumors within 5 years 34. In contrast, advanced and unresectable gastric cancers have a poor prognosis with an expected survival of few months. Endoscopic ultrasonography is the preferred technique for defining the depth of invasion into the gastric wall (pT stage).
Endoscopic resection is recommended for early gastric cancers with low probability of metastasising to lymph nodes. Risk factors associated with the development of nodal metastases, for which surgery with lymph-node dissection should be considered, include submucosal invasion, tumor diameter greater than 20-30 mm, vascular venous or lymphatic invasion, depressed or ulcerated macroscopic subtypes and undifferentiated histology 35. Treatment for advanced gastric cancer is based on surgery and chemo-radiation therapy. For patients with unresectable gastric cancer, systemic therapy is the only approach, encompassing conventional chemotherapy and targeted therapies. The latter include monoclonal antibodies directed against HER2, VEGFR2 and immune checkpoint inhibitors 36,37. According to the most recent European recommendations 38 the only established predictive biomarker for the treatment of gastric cancer is HER2 status, evaluated by HER2 immunohistochemistry and ERBB2 in situ hybridization to select patients with unresectable or metastatic gastric cancer for anti-HER2 based therapies. Heterogeneity in HER2 assessment in gastric cancer has been widely documented 39 and this is of practical importance when HER2 evaluation is performed on endoscopic biopsies: a minimum set of 5 biopsies has shown to be necessary for a reliable HER2 assessment 40-41.
Emerging predictive biomarkers for selecting gastric cancer patients who may benefit from immune-checkpoint inhibitor-based immunotherapies include microsatellite instability (MSI)-high status 42, EBV infection 43, PD-L1 expression (combined positive score ≥ 1%) 44, tumor mutation load and density of intra-tumoral CD8+ T-cells 45.
Adverse prognostic factors in resectable cases include higher pT and pN stages 46, limited lymph node dissection, lymphatic and vascular invasion, and involvement of surgical margins.
MICROSCOPIC FINDINGS AND HISTOPATHOLOGICAL CLASSIFICATIONS
Gastric cancer presents a variability of morphological phenotypes, as reflected by the large number of histopathological classifications proposed over time 47. The histopathological classifications most commonly used include those proposed by Laurén 48 and the World Health Organization (WHO) 23.
The Laurén classification 48 (Tab. I) distinguishes two major types, intestinal and diffuse. The former, is composed of glands or papillae, while the latter shows an infiltrative growth pattern and is composed of tumor cells without cellular cohesion. Tumors presenting both intestinal and diffuse components are termed mixed carcinomas. Solid, poorly differentiated or undifferentiated carcinomas that do not fit in one of these subtypes are placed in the indeterminate category. Despite dating back to 1965, Laurén classification is still relevant, as it distinguishes subtypes with distinct epidemiologic settings, clinicopathologic profiles and biological behaviors. As an example, in view of their cohesive nature, intestinal type gastric cancers have the ability to survive more easily into venous vessels and tend to metastasise haematogenously, while the poorly cohesive phenotype of diffuse gastric cancer tends to disseminate through peritoneal surfaces. Mixed gastric cancer shows a poorer prognosis compared to intestinal or diffuse types 49 and a dual metastatic pattern (hematogenous metastases and peritoneal dissemination with lymph node metastases) 50, probably because of the cumulative adverse effect of the two components within a single tumor.
The WHO classification 23 (Tab. I) distinguishes five main histopathological subtypes of gastric cancers (Fig. 5): tubular adenocarcinoma, composed of tubular, glandular or acinar structures of variable diameter and various degrees of differentiation (some solid carcinomas may be classified as high-grade tubular adenocarcinomas); papillary carcinoma, showing finger-like papillary architecture, eventually admixed with glandular structures (tubulo-papillary phenotype); poorly cohesive carcinoma, composed of tumor cells isolated or in small clusters lacking cellular cohesion; mucinous adenocarcinoma, defined by the presence of mucin pools accounting for > 50% of the tumor; and mixed carcinomas, presenting a distinct tubulo-papillary and poorly cohesive component. In mixed carcinomas, the two components may be intermingled, adjacent, or completely separated. Providing that the two components are clearly identified within the tumor, there is no minimum cell percentage defining this entity.
Grading system (low-grade or high-grade gastric adenocarcinoma) applies primarily to tubular, papillary and tubulo-papillary subtypes 23. Tubular and papillary carcinomas roughly correspond to intestinal type gastric cancers, while poorly cohesive carcinomas correspond to the diffuse subtype by Laurén.
The 2019 WHO Classification of digestive system tumors stresses the importance of distinguishing different subtypes within the poorly cohesive carcinoma category, based on presence and quantity of signet ring cells. By definition, a signet ring cell has an abundant mucin vacuole filling the cytoplasm and pushing the nucleus at the cell periphery. Poorly cohesive carcinomas of the signet ring cell type are composed predominantly or exclusively (e.g. > 90%) of signet ring cells, while non-signet ring cell type (i.e. not otherwise specified) poorly cohesive carcinomas are composed (or show a component) of poorly cohesive and infiltrating cells without a classic signet ring cell morphology. It is important to recognise this latter subtype of poorly cohesive gastric cancer, as it presents poorer prognosis when compared to pure signet ring cell carcinomas 51.
The gastric cancer histopathological classification proposed by the Japanese Gastric Cancer Association (JGCA) is mainly used by Asian pathologists 52. Noteworthy, in the last version of the JGCA and the WHO classifications, gastric cancer expert pathologists have built a table showing the similarities of the two classification systems and corresponding entities.
To improve standards of gastric cancer reporting, macroscopic and histological examination should follow a specific checklist, as presented in Table I.
EARLY GASTRIC CANCER
Early gastric cancer (EGC) is carcinoma limited to the gastric mucosa and/or submucosa regardless of lymph node status with good prognosis 52. Unfortunately, some EGC will have nodal metastases and recent studies have focused on key parameters that could be associated with worse prognosis 53. In particular, size, depth of infiltration, and histological type of tumors, as well as the distribution of nodal metastases, are predictors of worse survival in this subset of tumors 54.
A dated but useful classification (see Tab. II) was introduced by Kodama 55 in 1983 that identifies growth patterns of EGC and correlates them with prognosis; more recent studies 56 have confirmed the importance of this classification which should be part of the pathology report both in surgical specimens but more importantly in endoscopic resections (Penetrating A growth subtype has a 10 year prognosis of 74% compared to 94% of non-penetrating A type).
IMMUNOHISTOCHEMICAL BIOMARKERS AND MOLECULAR SUBTYPES
Gastric cancer is the result of accumulated genomic damage that affects essential cellular functions for cancer development. Multiple gene mutations, somatic copy number alterations, epigenetic and transcriptional changes have been detected in gastric cancer, highlighting its molecular heterogeneity. Through high-throughput genomic analysis, several groups have analyzed and deciphered the molecular alterations of gastric cancer at high resolution, attempting to achieve integrated molecular classification schemes which recognise molecular entities with different molecular signatures and clinical phenotypes. These classifications include the Singapore-Duke group classification 57, based on gene expression profiling, and the molecular classifications proposed by The Cancer Genome Atlas (TCGA) 58, and the Asian Cancer Research Group (ACRG) 59, both based on the integrative analysis of multiple genomic and proteomic data. These molecular classifications have been proposed as a roadmap for gastric cancer prognostic evaluation and targeted therapy approaches. However, the three molecular classifications overlap only partially, highlighting the need for a consensual patient stratification.
The landmark study of gastric cancer molecular-based stratification was carried out by The Cancer Genome Atlas (TCGA) research network 58, which defines four molecular subtypes: EBV-associated gastric cancers, characterized by recurrent PIK3CA mutations, high levels of DNA hypermethylation, frequent JAK2 and CD274 (PD-L1) amplification and enrichment in genes involved in immune signalling; MSI-high gastric cancer, characterized by MLH1 silencing and consequent high levels of DNA hypermethylation; genomically stable gastric cancer, associated with a diffuse morphology and recurrent CDH1 and RHOA events; gastric cancer with chromosomal instability exhibiting a high number of TP53 mutations and amplifications of tyrosine kinase receptors. The prognostic and predictive value of TCGA four-tiered molecular classification has been highlighted: EBV-associated and MSI-high gastric cancers present the best prognostic features and may respond to targeted immunotherapies, chromosomal unstable tumors present a moderately poor prognosis but show sensitivity to chemotherapy, while genomically stable tumors show the worst prognosis and are resistant to chemotherapy 42,59.
There is partial correlation between histopathological and molecular classifications. EBV-associated gastric cancer shows the features of gastric cancer with lymphoid stroma (see below) in up to 80% of EBV+ cases (Fig. 6a); some cases present Crohn’s disease-like lymphoid reaction, characterised by the presence of numerous lymphoid follicles with active germinal centres at the advancing edge of the tumor 60; conventional-type histology, with scant lymphocytic infiltrate, is observed in a minority of cases. MSI-high gastric cancers may also present abundant intratumoral and peritumoral lymphocytic infiltrate. EBV infection and MSI-high status represent two alternative pathways of gastric carcinogenesis and mutually exclusive gastric cancer molecular subtypes 61, with distinct transcriptional profiles, the former enriched by genes related in the immune response and the latter associated with mitosis and cell cycle biological terms 62. Genomically stable gastric cancers show predominantly diffuse type histology 58. When compared to pure signet ring cell carcinomas, poorly cohesive carcinomas classified as not otherwise specified show a distinct genomic profile, enriched by TP53, RHOA, SMAD4, BRAF and PIK3CA mutations 51. Gastric cancers with chromosomal instability mostly present intestinal morphology 58.
Overall, tumor morphology may provide insight into tumor biology and should be used as a frame for the identification of clinically relevant subgroups, as the backbone for building algorithms for directed and cost-effective molecular characterization. Moreover, practical algorithms based on immunohistochemistry and in situ hybridization can be applied in the routine diagnostic practice to translate specific immunophenotypes into molecular subgroups with prognostic and predictive significance 63,64. Thus, positive in situ hybridization for EBV-encoded small RNA (EBER) distinguishes EBV-associated gastric cancer; loss of expression of DNA mismatch repair proteins (MLH1, MSH2, MSH6, PMS2) identifies most of gastric cancers with MSI-high status; genomically stable gastric cancers are identified by the poorly cohesive morphology and abnormal E-cadherin immunoreactivity (decreased membranous, dotted, cytoplasmic, or absent); and p53 aberrant expression (overexpression or total loss) distinguishes a subset of chromosomal unstable gastric cancers with TP53 activation 64.
In poorly differentiated or undifferentiated gastric cancers, in which epithelial differentiation is not morphologically evident, pancytokeratin and EMA immunohistochemistry may highlight the epithelial nature of the neoplasm and distinguish it from aggressive lymphomas, metastatic melanoma, germ cell neoplasms or other malignant neoplasms with epithelioid morphology.
Very well differentiated gastric cancers should be distinguished from gastritis cystica profunda, a benign lesion characterised by the displacement of gastric foveolar epithelium, gastric glands and mucin into the gastric wall or serosa. Gastritis cystica profunda usually develops in stomachs subjected to traumatism (e.g. surgery, gastroenterostomy) as the result of chronic inflammation, direct injury and ischemia 65. A helpful feature in distinguishing gastritis cystica profunda from adenocarcinoma is the presence of a rim of lamina propria-like stroma surrounding the cystically dilated glands, sometimes associated with smooth muscle fibres from the muscularis mucosae. Gastric adenocarcinoma may coexist with gastritis cystica profundal 66 and the distinction between the two lesions may be sometimes challenging (Fig. 7).
Rare histotypes of gastric carcinoma
Uncommon histological variants account for about 5% of gastric cancer and according to the WHO 2019 classification of digestive system tumors 23, encompass i) squamous cell carcinoma; ii) adenosquamous carcinoma; iii) and undifferentiated carcinoma.
Squamous cell carcinoma of the stomach is a carcinoma with evidence of squamous cell differentiation, in the absence of other morphologic aspects. It is preferentially located in upper part of the stomach and is extremely rare, accounting for less than 0.1% of gastric cancers. Thorough tumor sampling is required to exclude the presence of other components. Potential pitfalls include metastases from a squamous cell carcinoma from another organs or extension from an esophageal squamous cancer. It is an aggressive disease, associated with poor patient prognosis.
Adenosquamous carcinoma of the stomach (Fig. 6d) is a malignant epithelial neoplasm composed of both squamous and adenocarcinomatous components. The squamous cell component should constitute at least a quarter of the whole neoplasm to render this diagnosis. It is extremely rare, accounting for 0.2% of all gastric cancers and preferentially affects males. It is predominantly located in the distal stomach. Immunohistochemistry for p40 may help confirm the presence of a morphologically suspected squamous cell component. Adenosquamous carcinoma is an aggressive neoplasm.
Gastric undifferentiated carcinoma has been recently recognized as a specific histotype of gastric cancer. It is an anaplastic carcinoma with no evidence of any type of tumor cell differentiation. Four subtypes are described, including i) large cell carcinoma with rhabdoid features, ii) pleomorphic carcinoma, iii) sarcomatoid carcinoma, and iv) carcinoma with osteoclast-like giant cells. Rhabdoid carcinomas account for about 6% of gastric cancers with a solid architecture. Undifferentiated carcinomas are usually large, fungating masses, composed of intermediate-to-large cells, often with pleomorphic elements. Pancytoketatin is usually expressed by neoplastic cells, while vimentin shows a characteristic perinuclear dot-like pattern of expression. A subset of such cancers exhibits loss of SMARCB1 (INI1) or SMARCA4 (BRG1) expression 67. Mismatch repair protein deficiency may be present. Differential diagnoses include carcinomas with lymphoid stroma (a subtype of adenocarcinoma), lymphomas, sarcomas and melanomas. It is a very aggressive disease, with a dismal prognosis.
Carcinoma with lymphoid stroma (Fig. 6a) is also known as medullary carcinoma or lymphoepithelioma-like carcinoma. It is characterized by irregular sheets, trabeculae, poorly developed tubular structures and isolated cells, embedded within a prominent lymphocytic infiltrate with occasional lymphoid follicles. The lymphoid infiltrate can be so prominent that immunohistochemical study may be necessary to confirm the epithelial nature of the tumor. It is often associated with Epstein-Barr virus infection, which may be identified by in situ hybridization, though as a similar morphology can be observed in gastric cancer with microsatellite instability 68. It is associated with a better prognosis in comparison with conventional adenocarcinoma.
Other types: primary gastric hepatoid carcinoma (composed by hepatocyte-like cells) (Fig. 6b), adenocarcinoma with enteroblastic differentiation (composed of clear cells arranged in tubulo-papillary structures) and yolk-sac tumor-like carcinoma share the immunohistochemical expression of alpha-fetoprotein and should be distinguished from a metastatic hepatocellular carcinoma or a germ cell neoplasm. Alpha-fetoprotein and primitive enterocyte differentiation biomarkers, such as SALL4, glypican-3 and claudin-6 are expressed in adenocarcinoma with enteroblastic differentiation and hepatoid gastric carcinoma 69,70. Biomarkers which help to distinguish between primary hepatoid gastric adenocarcinoma from hepatocellular carcinoma metastases include SALL4 and claudin-6 expression in hepatoid gastric cancer and loss of SMARCB1 (INI1) immunoreactivity in hepatocellular carcinoma 71,72. Micropapillary carcinoma (Fig. 6c), shows small aggregated of neoplastic cells without fibrovascular cores within empty clefts and is associated with a poor prognosis 73. In this subtype, epithelial membrane antigen (EMA) and E-cadherin show a distinctive inside-out staining pattern with loss of immunoreactivity at the stroma interface. Gastric adenocarcinoma of fundic-gland type (chief cell predominant, parietal cell predominant, or mixed phenotype) account for about 1% of early gastric cancers and has been more frequently described in Asia 27. It derives from the so-called oxyntic-type adenoma and shows immunoreactivity for pepsinogen I and MUC6, suggesting a predominant chief cell differentiation. This subtype is rather indolent, with a limited propensity to lymph node dissemination. Other types include parietal cell carcinoma and Paneth cell carcinoma and these are regarded as subtypes of gastric adenocarcinoma according to the 2019 WHO classification 23.
Hereditary gastric cancer syndromes
Three major hereditary autosomal dominant syndromes affecting the stomach have been described: hereditary diffuse gastric cancer (HDGC), gastric adenocarcinoma and proximal polyposis of the stomach (GAPPS) and familial intestinal gastric cancer (FIGC) (Tab. III). Moreover, several other hereditary cancer syndromes are characterized by an increased risk of gastric cancer, namely classic and attenuated FAP, MUTYH-associated polyposis, Peutz-Jeghers syndrome, juvenile polyposis syndrome, Lynch Syndrome, Li-Fraumeni syndrome, hereditary breast and ovarian cancer syndrome, and Cowden syndrome 74.
HEREDITARY DIFFUSE GASTRIC CANCER (HDGC)
HDGC is an autosomal dominant cancer syndrome defined by the presence of germline variants in CDH1 or CTNNA1 genes and characterized by increased risk of diffuse (poorly cohesive) gastric cancer and lobular breast cancer 75. Families fulfilling genetic testing criteria for HDGC (Tab. III) but without CDH1 or CTNNA1 germline variants, should be defined as “HDGC-like” families 76.
Disease penetrance and clinical features
HDGC penetrance in proven mutation carriers is incomplete and variable between families 77. According to recent estimates, the risk of DGC is 42% for males and 33% for females while the lifetime risk of lobular breast cancer ranges from 42 to 55% 76. The time course from early to advanced HDGC is unpredictable 78 and prophylactic/risk reduction total gastrectomy in early adulthood is advised, regardless of endoscopic findings 76. Indeed, appropriate endoscopic surveillance, also with advanced imaging endoscopy, fails to detect precursor or invasive carcinoma foci in up to 80% of cases 79. At the time of clinical presentation, almost the totality of affected individuals presents with advanced and incurable disease. In women, annual breast magnetic resonance imaging is advised, starting at 30 years of age 76.
Histopathological analysis of prophylactic (risk-reducing) total gastrectomies reveals, in the majority of the cases 80, multiple and tiny (< 0.1 mm to 16 mm) foci of intramucosal (pT1a) signet ring cell carcinoma 81 (Fig. 5c). Two intraepithelial precursor lesions (pTis) of signet ring cell carcinoma have been recognised exclusively in CDH1 carriers, namely in situ SRCC, corresponding to the presence of signet ring cell within the basal membrane substituting normal epithelial cells, and pagetoid spread of signet ring cells, corresponding to a row of signet ring below the preserved epithelium of glands and foveolae, but still contained within the basal membrane 82. A proportion of intramucosal carcinoma foci from CDH1 carriers progress unpredictably to advanced disease, with diffuse infiltration of the gastric wall, peritoneal dissemination and metastases to distant organs. Advanced HDGC shows the features of poorly cohesive (diffuse) gastric cancer and is not distinguishable from the sporadic setting, except for the presence of multifocal intramucosal foci and precursor lesions in the mucosa distant from the tumor bulk 76. In contrast to early HDGC, composed of bona fide signet ring cells with an “indolent” phenotype, advanced HDGC shows pleomorphic, bizarre and diffusely infiltrative neoplastic cells with increased proliferation and activation of oncogenic events 83,84. The finding of “aggressive” histopathological features in endoscopic biopsy specimens from CDH1 carriers is suggestive of advanced disease and should be reported in the pathology report to prompt staging and clinical intervention 78.
Consistent with biallelic inactivation of the CDH1 gene and supporting the key role of E-cadherin loss for tumor initiation, E-cadherin expression is usually abnormal in precursor and invasive cancer foci. Diverse E-cadherin staining patterns have been described in HDGC, including complete loss of expression, reduced membranous immunoreactivity and “dotted” or cytoplasmic staining 83. It should be clarified that HDGC may show retained E-cadherin immunoreactivity and that E-cadherin staining should not be used as a pre-screening method to select patients eligible for germline CDH1 variant analysis.
The pathology of HDGC is unique and diagnostic expertise is needed to provide high quality diagnoses, both in biopsies and in resection specimens. Specifically, criteria for the identification of signet ring cell lesions should be strictly followed in order to diminish the risk of over diagnosing nonspecific changes and mimics of signet ring cells, such as globoid transformation and vacuolization of the superficial epithelium, xanthomatous cells, and artefacts secondary to cell autolysis. Second opinion by an independent pathologist with experience in the field should always be sought.
In HDGC patients presenting both lobular breast cancer and diffuse gastric cancer, a metastatic tumor should be considered and can be morphologically indistinguishable 85. Breast-associated immunomarkers are oestrogen receptor, BRST-2 (GCDFP-15) and mammaglobin, while the expression of CK20 and HNF4A may favour a diagnosis of gastric cancer 86.
GASTRIC ADENOCARCINOMA AND PROXIMAL POLYPOSIS OF THE STOMACH (GAPPS)
GAPPS is an autosomal dominant cancer predisposition syndrome associated with an increased risk of gastric cancer, arising in the context of polyposis of the proximal stomach. The genetic cause of GAPPS corresponds to germline point variants in the promoter 1B of the APC gene 87. Accordingly, GAPPS is defined as a variant of FAP with an exclusive gastric phenotype. Diagnostic criteria for GAPPS are listed in Table III. To consider a diagnosis of GAPPS, the presence of polyposis elsewhere in the gastrointestinal tract should be ruled out.
GAPPS penetrance is also incomplete, as proven by the evidence of normal endoscopies in elderly obligate carriers 88. The age of onset of gastric cancer is variable, ranging from 23 to 75 years. Fundic gland polyposis carpeting the gastric body and fundus has been detected as early as 10 years of age 88. Recommendations on the management of GAPPS should be decided on a case-by-case basis. Clinical strategies encompass endoscopic surveillance with biopsies and/or polypectomies and prophylactic/risk-reduction gastrectomy 88.
GAPPS is characterized by multiple fundic gland polyps carpeting the gastric body and fundus, some of which show foveolar-type dysplasia and by the presence of hyperproliferative aberrant pits, corresponding to hyper-proliferative and disorganized oxyntic glands around gastric pits 89. Other lesions include hyperplastic polyps, intestinal-type and foveolar-type adenomas with low- and high-grade dysplasia, as well as mixed polyps with FGP-like, adenomatous and hyperplastic features 89. Gastric adenocarcinomas are intestinal-type or mixed-type 88.
Prolonged therapy with proton-pump inhibitors could cause the development of multiple FGPs and sporadic fundic gland polyposis. According to the clinical criteria to consider GAPPS diagnosis (Tab. III), upper endoscopy should be repeated after discontinuation of therapy and appropriate off-treatment interval 88.
FAMILIAL INTESTINAL GASTRIC CANCER (FIGC)
Familial intestinal gastric cancer (FIGC) is an autosomal dominant cancer syndrome associated with an increased risk of intestinal-type gastric cancer 90. Diagnostic criteria (Tab. III) differ depending upon the incidence of gastric cancer in the population analysed. The genetic cause underlying the disease remains to be fully elucidated, although recent studies brought up the possibility of a distinctive polygenic cause for the disease 91.
The clinical phenotype of gastric cancer patients fulfilling the clinical criteria for FIGC has been characterized recently 91. The lifetime risk of gastric cancer is 66% for both sexes and the mean age at diagnosis is 72 years, approximately 10 years earlier than patients with sporadic intestinal-type gastric cancers. The disease spectrum is broad, encompassing 18 cancer types including colorectal and breast cancer.
FIGC displays macroscopic and histopathological features that are undistinguishable from intestinal-type sporadic gastric cancer.
Post neo-adjuvant treatment tumor regression grade in gastric adenocarcinoma
Preoperative neo-adjuvant chemotherapy or combined radiotherapy and chemotherapy (neo-CRT) has become the standard approach for locally advanced gastric carcinomas. Pathological tumor regression grading (TRG) systems, which aim to evaluate and quantify the amount of residual tumor and/or regressive changes following neo-CRT, should be applied to all resections specimens.
TRG scoring permits prognostic stratification of tumors, indeed, complete pathological response is significantly associated with better outcome – at least in some series – and this classification into prognostic classes is the basis for personalized treatment and follow-up strategy.
PROBLEMS IN TRG ASSIGNMENT
The presence of several validated classification systems for TRG has however led to some confusion as to which system should be preferentially applied. The presence of similar but not “exactly” similar TRG systems may, in part, explain why studies on the prognostic impact of response have yielded variable results 92.
There are many possible reasons which explain the lack of a universally accepted TRG system: 1) absence of standardized different sampling methods which could lead to over-diagnosis of complete pathological tumor regression and this may in part explain its variable prognostic impact. Indeed, the complete microscopic assessment of the entire ulcerated/scarring area should be performed and this is absolutely mandatory if no tumor is identified in the initial blocks; 2) not all classifications take into account the evaluation of response in loco-regional lymph nodes; 3) there is a relatively low concordance rate among pathologists in TRG assignment; 4) systems with a higher number of tiers (more than 4) do not offer any clear cut prognostic advantage 93.
TRG SYSTEMS FOR GASTRIC CANCER
Gastric cancer specific TRG systems have been proposed starting from the 2003 Becker system 94 which requires the histologic assessment of the entire macroscopically identifiable residual tumor or the fibrous areas. The Becker system is based on the percentage of vital tumor tissue with no integrated nodal evaluation: TRG1 - complete tumor regression (TRG 1a: 0% residual tumor) or subtotal tumor regression (TRG 1b: < 10% residual tumor); TRG 2 - partial tumor regression (10% to 50% residual tumor); TRG 3 - minimal/no tumor regression per tumor bed (> 50% residual tumor cells with or without signs of tumor regression). Recently, an international group of experts, through a Delphi survey, has proposed a 4-tiered system based on the modified Becker grading system. The novelty of this system is the addition of the evaluation of response in metastatic lymph nodes (complete, partial, or no nodal response) and this seems add strength to the system 95.
The pathology report of gastric resections specimens requires a standardized approach as well as an in depth knowledge of prognostic and treatment associated factors. Furthermore, the recognition of hereditary conditions is important and requires cross-talk between the pathologist and clinicians.
Figures and tables
|Procedure||Endoscopic resectionPartial gastrectomy: specify if proximal, distal, otherTotal gastrectomyOther|
|Specimen description||Endoscopic resectionDimension of mucosal surface (cm) and depth (cm)|
|GastrectomyLength (cm) of lesser and greater curvatureLength (cm) of duodenal and oesophageal segments, if applicable|
|Macroscopic examination||Tumor not identified macroscopically|
|Tumor location (gastric region): cardia, fundus, body, transitional zone, antrum, pylorus|
|Tumor location (gastric curvatures and walls): lesser curvature, greater curvature, anterior wall, posterior wall|
|Tumor size: greatest dimension (cm) or three dimensions (cm)|
|Tumor macroscopic appearance Borrmann type I: polypoid/fungating Borrmann type II: ulcerated mass Borrmann type III: infiltrative neoplasm with ulceration Borrmann type IV: infiltrative neoplasm without ulceration|
|Margins||Endoscopic resectionMucosal margin Involved by invasive carcinoma Involved by dysplasia (low-grade/high-grade) Uninvolved by invasive carcinoma or dysplasia Deep margin Involved by invasive carcinoma Involved by dysplasia (low-grade/high-grade) Uninvolved by invasive carcinoma or dysplasia|
|GastrectomyEsophageal (proximal) margin Involved by invasive carcinoma Involved by dysplasia (low-grade/high-grade) Uninvolved by invasive carcinoma or dysplasia Duodenal (distal) margin Involved by invasive carcinoma Involved by dysplasia (low-grade/high-grade) Uninvolved by invasive carcinoma or dysplasia Omental (radial) margin Involved by invasive carcinoma (greater and/or lesser omental margin) Uninvolved by invasive carcinoma|
|Gastric cancer histological subtype||Laurén classification55: Diffuse type Intestinal type Mixed type Indeterminate WHO classification (major types and rare variants): Tubular adenocarcinoma Papillary adenocarcinoma Tubulo-papillary adenocarcinoma Poorly cohesive carcinoma: signet ring cell type/not otherwise specified Mucinous adenocarcinoma Mixed adenocarcinoma Gastric squamous carcinoma Gastric adenosquamous carcinoma Gastric undifferentiated carcinoma Gastric cancer with lymphoid stroma Hepatoid carcinoma Alpha-fetoprotein producing gastric cancer (adenocarcinoma with enteroblastic differentiation, yolk-sac tumor like carcinoma) Micropapillary adenocarcinoma Gastric adenocarcinoma of the fundic gland type Mucoepidermoid carcinoma Paneth cell carcinoma Parietal cell carcinoma|
|Histologic grade||Only applicable to tubular and papillary adenocarcinoma: Low grade High grade|
|Pathological stage: descriptors||m (multiple primary tumors) r (recurrent) y (post-treatment)|
|Pathological stage:primary tumor (pT)||pTX: primary tumor cannot be assessed pT0: no evidence of primary tumor pTis: in situ SRC carcinoma, pagetoid progression of SRCs, high-grade dysplasia pT1a: tumor invades the lamina propria or muscularis mucosae pT1b: tumor invades the submucosa pT2: tumor invades the muscularis propria pT3: tumor penetrates the subserosal connective tissue without invasion of the visceral peritoneum or adjacent structures pT4a: tumor invades the serosa (visceral peritoneum) pT4b: tumor invades adjacent structures/organs|
|Lymph node examination||Number of lymph nodes involved Lesser omentum Greater omentum Other Number of lymph nodes examined Lesser omentum Greater omentum Other Ratio between lymph nodes involved and examined|
|Pathological stage:regional lymph nodes (pN)||pNX: regional lymph node(s) cannot be assessed pNX: regional lymph node(s) cannot be assessed pN0: no regional lymph node metastasis pN1: metastasis in one or two regional lymph nodes pN2: metastasis in three to six regional lymph nodes pN3a: metastasis in seven to 15 regional lymph nodes pN3b: metastasis in 16 or more regional lymph nodes|
|Pathological stage:distant metastasis||Not applicable (pM status required only if confirmed pathologically) pM1: distant metastasis(es) (specify site)|
|Lymphovascular invasion||Not identified Present Cannot be determined|
|Perineural invasion||Not identified Present Cannot be determined|
|Treatment effect||No known presurgical therapy Present Complete response (no viable cancer cells) – score 0 Near complete response (single or rare small groups of cancer cells) – score 1 Partial response (evident tumor regression but more than single or rare small groups of cancer cells) – score 2 Poor or no response (no evident tumor regression) – score 3 Cannot be determined|
|Additional findings||Helicobacter pylori infection Chronic gastritis (lymphoid follicles, neutrophilic activity, erosion/ulceration) Glandular atrophy Intestinal metaplasia Dysplasia Polyps: specify type|
|Ancillary studies||Add any relevant ancillary study performed|
|Comments||Add any relevant comment|
|Small mucosal (M)||Intramucosal EGCs measuring < 4 cm|
|Small mucosal (SM)||Intramucosal EGCs minimally invading submucosa measuring < 4 cm|
|Supermucosal (M)||Intramucosal EGCs measuring > 4 cm|
|Supermucosal, (SM)||Intramucosal EGCs minimally invading submucosa measuring > 4 cm|
|PEN (penetrating) (A)||EGCs massively invading submucosa with nodular pattern measuring < 4 cm|
|PEN (penetrating) (B)||EGCs massively invading submucosa with saw tooth pattern measuring < 4 cm|
|Syndrome||Genetic testing criteria||Recommended genetic testing||Histopathological findings|
|HDGC||Family criteria (first and second relatives): At least 2 cases of GC in family regardless of age, with at least one diffuse GC At least 1 case of diffuse GC any age and ≥1 case of LBC < 70 years in different family members At least 2 cases of lobular breast cancer in family members < 50 years Individual criteria: Diffuse GC < 50 years Diffuse GC at any age in individuals of Mãori ethnicity Diffuse GC at any age in individuals with a personal or family history (1st degree) of cleft lip/cleft palate History of diffuse GC and lobular breast cancer, both diagnosed < 70 years Bilateral lobular breast cancer, diagnosed < 70 years Gastric in situ signet ring cells and/or pagetoid spread of signet ring cells in individuals < 50 years||CDH1genetic analysisCTNNA1mutation analysis||Diffuse (poorly cohesive) GC and precursor lesions (in situ signet ring cell carcinoma, pagetoid spread of signet ring cells) LBC|
|GAPPS||Essential criteria: Phenotypic features: proximal polyposis with antral sparing; no evidence of colorectal or duodenal polyposis; > 100 polyps carpeting the proximal stomach in the index patient or > 30 polyps in a first-degree relative of another patient; predominantly FGPs and/or fundic gland-like polyps Proband or relative with either dysplastic FGPs or GC Mutation in the promoter 1B (YY1 binding motif) of APC gene Supportive criteria: Autosomal dominant patern of inheritance Spectrum of other histological features, including hyperproliferative aberrant pits, hyperplastic polyps, gastric-type adenomas||APC promoter 1b mutation analysis||FGPs (with dysplasia)Hyperplastic polypsHyperproliferative aberrant pitsIntestinal and foveolar adenomasMixed polyps with FGP-like, adenomatous and hyperplastic featuresIntestinal and mixed GC|
|FIGC||IGCLC criteria in high incidence countries: Intestinal GC in three or more relatives; and One being a first-degree relative of the other two; and Two or more successive generations affected; and Intestinal GC <50 years in one or more patients; and Exclusion of gastric polyposis. IGCLC criteria in low incidence countries: Intestinal GC in two or more first-degree relatives; Intestinal GC in second-degree relatives, one diagnosed < 50 years Intestinal GC in three or more relatives at any age. Proposal of new criteria: GC in two or more relatives at any age; and At least one intestinal GC||NA||Intestinal GC|
- Bray F, Ferlay J, Soerjomataram I. Global cancer statistics 2018: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68:394-424. DOI
- Gullo I, Carneiro F, Oliveira C. Heterogeneity in gastric cancer: From pure morphology to molecular classifications. Pathobiology. 2018; 85:50-63. DOI
- Eusebi LH, Telese A, Marasco G. Gastric cancer prevention strategies: A global perspective. J Gastroenterol Hepatol. 2020. DOI
- Fukayama M, Abe H, Kunita A. Thirty years of epstein-barr virus-associated gastric carcinoma. Virchows Arch. 2020; 476:353-5. DOI
- Sanduleanu S, Jonkers D, De Bruine A. Non-helicobacter pylori bacterial flora during acid-suppressive therapy: differential findings in gastric juice and gastric mucosa. Aliment Pharmacol Ther. 2001; 15:379-88. DOI
- Spoto CPE, Gullo I, Carneiro F. Hereditary gastrointestinal carcinomas and their precursors: An algorithm for genetic testing. Semin Diagn Pathol. 2018; 35:170-83. DOI
- van der Post RS, Carneiro F. Emerging concepts in gastric neoplasia: Heritable gastric cancers and polyposis disorders. Surg Pathol Clin. 2017; 10:931-45. DOI
- Correa P. Human gastric carcinogenesis: a multistep and multifactorial process--first american cancer society award lecture on cancer epidemiology and prevention. Cancer Res. 1992; 52:6735-40.
- Plummer M, Franceschi S, Vignat J. Global burden of gastric cancer attributable to helicobacter pylori. Int J Cancer. 2015; 136:487-90. DOI
- Polk DB, Peek RM. Helicobacter pylori: gastric cancer and beyond. Nat Rev Cancer. 2010; 10:403-14. DOI
- Ferreira RM, Machado JC, Figueiredo C. Clinical relevance of helicobacter pylori vaca and caga genotypes in gastric carcinoma. Best Pract Res Clin Gastroenterol. 2014; 28:1003-15. DOI
- Persson C, Canedo P, Machado JC. Polymorphisms in inflammatory response genes and their association with gastric cancer: a huge systematic review and meta-analyses. Am J Epidemiol. 2011; 173:259-70. DOI
- Mahmud N, Stashek K, Katona BW. The incidence of neoplasia in patients with autoimmune metaplastic atrophic gastritis: a renewed call for surveillance. Ann Gastroenterol. 2019; 32:67-72. DOI
- Sipponen P, Price AB. The Sydney system for classification of gastritis 20 years ago. J Gastroenterol Hepatol. 2011; 26:31-4. DOI
- Meining A, Bayerdorffer E, Muller P. Gastric carcinoma risk index in patients infected with helicobacter pylori. Virchows Arch. 1998; 432:311-4. DOI
- Rugge M, Meggio A, Pennelli G. Gastritis staging in clinical practice: the olga staging system. Gut. 2007; 56:631-6. DOI
- Pimentel-Nunes P, Libânio D, Marcos-Pinto R. Management of epithelial precancerous conditions and lesions in the stomach (maps ii): European society of gastrointestinal endoscopy (esge), european helicobacter and microbiota study group (ehmsg), european society of pathology (esp), and sociedade portuguesa de endoscopia digestiva (sped) guideline update 2019. Endoscopy. 2019; 51:365-88. DOI
- Spechler SJ, Merchant JL, Wang TC. A summary of the 2016 James W. Freston conference of the american gastroenterological association: Intestinal metaplasia in the esophagus and stomach: origins, differences, similarities and significance. Gastroenterology. 2017; 153:e6-e13. DOI
- Reis CA, David L, Correa P. Intestinal metaplasia of human stomach displays distinct patterns of mucin (muc1, muc2, muc5ac, and muc6) expression. Cancer Res. 1999; 59:1003-7.
- Leung WK, Lin SR, Ching JY. Factors predicting progression of gastric intestinal metaplasia: Results of a randomised trial on helicobacter pylori eradication. Gut. 2004; 53:1244-9. DOI
- Goldenring JR, Nam KT, Wang TC. Spasmolytic polypeptide-expressing metaplasia and intestinal metaplasia: time for reevaluation of metaplasias and the origins of gastric cancer. Gastroenterology. 2010; 138:2207-2210. DOI
- Valente P, Garrido M, Gullo I. Epithelial dysplasia of the stomach with gastric immunophenotype shows features of biological aggressiveness. Gastric Cancer. 2015; 18:720-8. DOI
- WHO. Classification of tumors. Digestive system tumors. Tumors of the stomach. WHO Classification of Tumors Editorial Board. IARC press: Lyon; 2019.
- Kim A, Ahn SJ, Park DY. Gastric crypt dysplasia: a distinct subtype of gastric dysplasia with characteristic endoscopic features and immunophenotypic and biological anomalies. Histopathology. 2016; 68:843-9. DOI
- Hackeng WM, Montgomery EA, Giardiello FM. Morphology and genetics of pyloric gland adenomas in familial adenomatous polyposis. Histopathology. 2017; 70:549-57. DOI
- Brosens LA, Wood LD, Offerhaus GJ. Pathology and genetics of syndromic gastric polyps. Int J Surg Pathol. 2016; 24:185-99. DOI
- Benedict MA, Lauwers GY, Jain D. Gastric adenocarcinoma of the fundic gland type: Update and literature review. Am J Clin Pathol. 2018; 149:461-73. DOI
- Ahn JY, Son DH, Choi KD. Neoplasms arising in large gastric hyperplastic polyps: Endoscopic and pathologic features. Gastrointest Endosc. 2014; 80:1005-1013.e1002. DOI
- Takayama Y, Ono Y, Mizukami Y. Comparative genome-wide analysis of gastric adenocarcinomas with hyperplastic polyp components. Virchows Arch. 2019; 475:383-9. DOI
- Carmack SW, Genta RM, Schuler CM. The current spectrum of gastric polyps: A 1-year national study of over 120,000 patients. Am J Gastroenterol. 2009; 104:1524-32. DOI
- Abraham SC, Nobukawa B, Giardiello FM. Fundic gland polyps in familial adenomatous polyposis: neoplasms with frequent somatic adenomatous polyposis coli gene alterations. Am J Pathol. 2000; 157:747-54. DOI
- Hamashima C. Cancer screening guidelines and policy making: 15 years of experience in cancer screening guideline development in japan. Jpn J Clin Oncol. 2018; 48:278-86. DOI
- Teh JL, Shabbir A, Yuen S. Recent advances in diagnostic upper endoscopy. World J Gastroenterol. 2020; 26:433-47. DOI
- Tsukuma H, Mishima T, Oshima A. Prospective study of “early” gastric cancer. Int J Cancer. 1983; 31:421-26.
- Pimentel-Nunes P, Dinis-Ribeiro M, Ponchon T. Endoscopic submucosal dissection: European society of gastrointestinal endoscopy (esge) guideline. Endoscopy. 2015; 47:829-54. DOI
- Bang YJ, Van Cutsem E, Feyereislova A. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of her2-positive advanced gastric or gastro-oesophageal junction cancer (toga): a phase 3, open-label, randomised controlled trial. Lancet. 2010; 376:687-97. DOI
- Fuchs CS, Tabernero J, Tomasek J. Biomarker analyses in regard gastric/gej carcinoma patients treated with vegfr2-targeted antibody ramucirumab. Br J Cancer. 2016; 115:974-82. DOI
- Smyth EC, Verheij M, Allum W. Gastric cancer: esmo clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016; 27:v38-v49. DOI
- Grillo F, Fassan M, Sarocchi F. HER2 heterogeneity in gastric/gastroesophageal cancers: from benchside to practice. World J Gastroenterol. 2016; 22:5879-87. DOI
- Grillo F, Fassan M, Ceccaroli C. The reliability of endoscopic biopsies in assessing HER2 status in gastric and gastroesophageal junction cancer: a study comparing biopsies with surgical samples. Transl Oncol. 2013; 6:10-6. DOI
- Gullo I, Grillo F, Molinaro L. Minimum biopsy set for HER2 evaluation in gastric and gastro-esophageal junction cancer. Endosc Int Open. 2015; 3:E165-70. DOI
- Le DT, Durham JN, Smith KN. Mismatch repair deficiency predicts response of solid tumors to pd-1 blockade. Science. 2017; 357:409-13. DOI
- Sohn BH, Hwang JE, Jang HJ. Clinical significance of four molecular subtypes of gastric cancer identified by the cancer genome atlas project. Clin Cancer Res. 2017. DOI
- Kulangara K, Zhang N, Corigliano E. Clinical utility of the combined positive score for programmed death ligand-1 expression and the approval of pembrolizumab for treatment of gastric cancer. Arch Pathol Lab Med. 2019; 143:330-7. DOI
- Topalian SL, Taube JM, Anders RA. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer. 2016; 16:275-87. DOI
- Sano T, Coit DG, Kim HH. Proposal of a new stage grouping of gastric cancer for tnm classification: International gastric cancer association staging project. Gastric Cancer. 2017; 20:217-25. DOI
- Solcia E, Klersy C, Mastracci L. A combined histologic and molecular approach identifies three groups of gastric cancer with different prognosis. Virchows Arch. 2009; 455:197-211. DOI
- Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand. 1965; 64:31-49.
- Zheng HC, Li XH, Hara T. Mixed-type gastric carcinomas exhibit more aggressive features and indicate the histogenesis of carcinomas. Virchows Arch. 2008; 452:525-34. DOI
- Carneiro F. Classification of gastric carcinomas. Current Diagnostic Pathology. 1997; 4:51-9.
- Kwon CH, Kim YK, Lee S. Gastric poorly cohesive carcinoma: a correlative study of mutational signatures and prognostic significance based on histopathological subtypes. Histopathology. 2018; 72:556-68. DOI
- Japanese gastric cancer association. Japanese classification of gastric carcinoma. 2017.
- Saragoni L. Upgrading the definition of early gastric cancer: better staging means more appropriate treatment. Cancer Biol Med. 2015; 12:355-61. DOI
- Saragoni L, Scarpi E, Ravaioli A. Early gastric cancer: clinical behavior and treatment options. Results of an Italian Multicenter Study on behalf of the Italian Gastric Cancer Research Group (GIRCG). Oncologist. 2018; 23:852-8. DOI
- Kodama Y, Inokuchi K, Soejima K. Growth patterns and prognosis in early gastric cancer. Superficially spreading and penetrating growth types. Cancer. 1983; 51:320-6.
- Saragoni L, Morgagni P, Gardni A. Early gastric cancer: diagnosis, staging, and clinical impact. Evaluation of 530 patients. New elements for an updated definition and classification. Gastric Cancer. 2013; 16:549-54. DOI
- Lei Z, Tan IB, Das K. Identification of molecular subtypes of gastric cancer with different responses to pi3-kinase inhibitors and 5-fluorouracil. Gastroenterology. 2013; 145:554-65. DOI
- TCGA. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014; 513:202-9. DOI
- Cristescu R, Lee J, Nebozhyn M. Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. Nat Med. 2015; 21:449-56. DOI
- Song HJ, Kim KM. Pathology of epstein-barr virus-associated gastric carcinoma and its relationship to prognosis. Gut Liver. 2011; 5:143-8. DOI
- Chiaravalli AM, Cornaggia M, Furlan D. The role of histological investigation in prognostic evaluation of advanced gastric cancer. Analysis of histological structure and molecular changes compared with invasive pattern and stage. Virchows Arch. 2001; 439:158-69. DOI
- Gullo I, Carvalho J, Martins D. The transcriptomic landscape of gastric cancer: Insights into epstein-barr virus infected and microsatellite unstable tumors. Int J Mol Sci. 2018; 19DOI
- Setia N, Agoston AT, Han HS. A protein and mrna expression-based classification of gastric cancer. Mod Pathol. 2016; 29:772-84. DOI
- Ahn S, Lee SJ, Kim Y. High-throughput protein and mrna expression-based classification of gastric cancers can identify clinically distinct subtypes, concordant with recent molecular classifications. Am J Surg Pathol. 2017; 41:106-15. DOI
- Machicado J, Shroff J, Quesada A. Gastritis cystica profunda: endoscopic ultrasound findings and review of the literature. Endosc Ultrasound. 2014; 3:131-4. DOI
- Choi MG, Jeong JY, Kim KM. Clinical significance of gastritis cystica profunda and its association with epstein-barr virus in gastric cancer. Cancer. 2012; 118:5227-33. DOI
- Agaimy A, Rau TT, Hartmann A. SMARCB1 (INI1)-negative rhabdoid carcinomas of the gastrointestinal tract: clinicopathologic and molecular study of a highly aggressive variant with literature review. Am J Surg Pathol. 2014; 38:910-20. DOI
- Gullo I, Oliveira P, Athelogou M. New insights into the inflamed tumor immune microenvironment of gastric cancer with lymphoid stroma: from morphology and digital analysis to gene expression. Gastric Cancer. 2019; 22:77-90. DOI
- Yamazawa S, Ushiku T, Shinozaki-Ushiku A. Gastric cancer with primitive enterocyte phenotype: An aggressive subgroup of intestinal-type adenocarcinoma. Am J Surg Pathol. 2017; 41:989-97. DOI
- Ushiku T, Uozaki H, Shinozaki A. Glypican 3-expressing gastric carcinoma: distinct subgroup unifying hepatoid, clear-cell, and alpha-fetoprotein-producing gastric carcinomas. Cancer Sci. 2009; 100:626-32. DOI
- Ushiku T, Shinozaki A, Shibahara J. Sall4 represents fetal gut differentiation of gastric cancer, and is diagnostically useful in distinguishing hepatoid gastric carcinoma from hepatocellular carcinoma. Am J Surg Pathol. 2010; 34:533-40. DOI
- Mochizuki K, Kawai M, Odate T. Smarcb1/ini1 is diagnostically useful in distinguishing α-fetoprotein-producing gastric carcinoma from hepatocellular carcinoma. Anticancer Res. 2018; 38:6865-8. DOI
- Roh JH, Srivastava A, Lauwers GY. Micropapillary carcinoma of stomach: a clinicopathologic and immunohistochemical study of 11 cases. Am J Surg Pathol. 2010; 34:1139-46. DOI
- Oliveira C, Pinheiro H, Figueiredo J. Familial gastric cancer: genetic susceptibility, pathology, and implications for management. Lancet Oncol. 2015; 16:e60-70. DOI
- Van der Post RS, Vogelaar IP, Carneiro F. Hereditary diffuse gastric cancer: updated clinical guidelines with an emphasis on germline cdh1 mutation carriers. J Med Genet. 2015; 52:361-74. DOI
- Blair VR MM, Carneiro F, Coit DG. Hereditary diffuse gastric cancer: updated clinical practice guidelines. Lancet Oncol. 2020; 21:e386-e97. DOI
- Roberts ME, Ranola JMO, Marshall ML. Comparison of cdh1 penetrance estimates in clinically ascertained families vs families ascertained for multiple gastric cancers. JAMA Oncol. 2019; 5:1325-31. DOI
- Gullo I, Devezas V, Baptista M. Phenotypic heterogeneity of hereditary diffuse gastric cancer: report of a family with early-onset disease. Gastrointest Endosc. 2018; 87:1566-75. DOI
- Mi EZ, Mi EZ, di Pietro M. Comparative study of endoscopic surveillance in hereditary diffuse gastric cancer according to cdh1 mutation status. Gastrointest Endosc. 2017. DOI
- Rocha JP, Gullo I, Wen X. Pathological features of total gastrectomy specimens from asymptomatic hereditary diffuse gastric cancer patients and implications for clinical management. Histopathology. 2018; 73:878-86. DOI
- Huntsman DG, Carneiro F, Lewis FR. Early gastric cancer in young, asymptomatic carriers of germ-line e-cadherin mutations. N Engl J Med. 2001; 344:1904-9. DOI
- Carneiro F, Huntsman DG, Smyrk TC. Model of the early development of diffuse gastric cancer in e-cadherin mutation carriers and its implications for patient screening. J Pathol. 2004; 203:681-7. DOI
- van der Post RS, Gullo I, Oliveira C. Histopathological, molecular, and genetic profile of hereditary diffuse gastric cancer: current knowledge and challenges for the future. Adv Exp Med Biol. 2016; 908:371-91. DOI
- Lee HE, Smyrk TC, Zhang L. Histologic and immunohistochemical differences between hereditary and sporadic diffuse gastric carcinoma. Hum Pathol. 2018; 74:64-72. DOI
- Mahmud N, Ford JM, Longacre TA. Metastatic lobular breast carcinoma mimicking primary signet ring adenocarcinoma in a patient with a suspected cdh1 mutation. J Clin Oncol. 2015; 33:e19-21. DOI
- van der Post RS, Bult P, Vogelaar IP. Hnf4a immunohistochemistry facilitates distinction between primary and metastatic breast and gastric carcinoma. Virchows Arch. 2014; 464:673-9. DOI
- Li J, Woods SL, Healey S. Point mutations in exon 1b of apc reveal gastric adenocarcinoma and proximal polyposis of the stomach as a familial adenomatous polyposis variant. Am J Hum Genet. 2016; 98:830-42. DOI
- Worthley DL, Phillips KD, Wayte N. Gastric adenocarcinoma and proximal polyposis of the stomach (gapps): a new autosomal dominant syndrome. Gut. 2012; 61:774-9. DOI
- de Boer WB, Ee H, Kumarasinghe MP. Neoplastic lesions of gastric adenocarcinoma and proximal polyposis syndrome (gapps) are gastric phenotype. Am J Surg Pathol. 2018; 42:1-8. DOI
- Caldas C, Carneiro F, Lynch HT. Familial gastric cancer: overview and guidelines for management. J Med Genet. 1999; 36:873-80.
- Carvalho J, Oliveira P, Senz J. Redefinition of familial intestinal gastric cancer: Clinical and genetic perspectives. J Med Genet. 2020. DOI
- Zhu Y, Sun Y, Hu S. Comparison of five tumor regression grading systems for gastric adenocarcinoma after neoadjuvant chemotherapy: a retrospective study of 192 cases from National Cancer Center in China. BMC Gastroenterol. 2017; 17:41. DOI
- Fanelli GN, Loupakis F, Smyth E. Pathological tumor regression grade classifications in gastrointestinal cancers: role on patients’ prognosis. Int J Surg Pathol. 2019; 27:816-35. DOI
- Becker K, Mueller JD, Schulmacher C. Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer. 2003; 98:1521-30.
- Tsekrekos A, Detlefsen S, Riddell R. Histopathologic tumor regression grading in patients with gastric carcinoma submitted to neoadjuvant treatment: results of a Delphi survey. Hum Pathol. 2019; 84:26-34. DOI
$authorString->getFullName() => Irene Gullo
$authorString->getFullName() => Federica Grillo
$authorString->getOrcid() => https://orcid.org/0000-0003-0193-5281
$authorString->getFullName() => Luca Mastracci
$authorString->getFullName() => Alessandro Vanoli
$authorString->getFullName() => Fatima Carneiro
$authorString->getFullName() => Luca Saragoni
$authorString->getFullName() => Francesco Limarzi
$authorString->getFullName() => Jacopo Ferro
$authorString->getOrcid() => https://orcid.org/0000-0003-0591-6723
$authorString->getFullName() => Paola Parente
$authorString->getFullName() => Matteo Fassan
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
© Società Italiana di Anatomia Patologica e Citopatologia Diagnostica, Divisione Italiana della International Academy of Pathology , 2020
How to Cite
- Abstract viewed - 3768 times
- PDF downloaded - 1491 times